Haematological malignancies
The sponsor’s clinical research activity is centred on aggressive blood cancers, with attention to diffuse large B-cell lymphoma and high-grade B-cell lymphoma arising from mature B-cells at advanced stages of differentiation.
- Diffuse large B-cell lymphoma
- High-grade B-cell lymphoma
- B-cell neoplasms
These studies reflect a focus on relapsed disease biology and treatment selection in aggressive lymphoma settings.
Relapsed and refractory leukaemia
Research also addresses patients with relapsed or refractory acute leukaemia, including both acute lymphoblastic leukaemia and acute myeloid leukaemia when curative options are no longer available.
- Acute lymphoblastic leukaemia
- Acute myeloid leukaemia
- Refractory haematologic disease
The therapeutic emphasis is on difficult-to-treat leukaemia populations with limited remaining treatment choices.
Molecularly guided oncology
The institute’s trials include interest in circulating tumour DNA and cell-free tumour DNA as tools for guiding treatment decisions in lymphoma care, linking molecular assessment with second-line therapy planning.
- Circulating tumour DNA
- Cell-free DNA
- Biomarker-directed treatment
This area connects liquid biopsy approaches with earlier identification of patients who may need alternate therapy.
Targeted treatment strategies
Another area of interest is the use of targeted agents in acute leukaemia, including combinations involving MEK inhibition and FLT3 inhibition for patients with relapsed or refractory disease.
- MEK pathway targeting
- FLT3-directed therapy
- Combination treatment in leukaemia
These studies place emphasis on precision-oriented options for advanced haematological malignancies.
